2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors
1999
Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem?
Alappan R, Buller G, Perazella M. Trimethoprim-Sulfamethoxazole Therapy in Outpatients: Is Hyperkalemia a Significant Problem? American Journal Of Nephrology 1999, 19: 389-394. PMID: 10393376, DOI: 10.1159/000013483.Peer-Reviewed Original ResearchConceptsSerum potassium concentrationSerum creatinine levelsTrimethoprim-sulfamethoxazole therapyBaseline serum potassium concentrationVariety of infectionsCreatinine levelsDay 5Treatment groupsPotassium concentrationControl groupMean serum potassium concentrationBlood urea nitrogen levelsDevelopment of hyperkalemiaLife-threatening hyperkalemiaMild renal insufficiencyDays of therapyHigher serum potassium concentrationsImmunodeficiency syndrome (AIDS) patientsUrea nitrogen levelsSerum glucose concentrationRelevant hyperkalemiaOral antibioticsRenal insufficiencyMost patientsSevere hyperkalemia
1998
Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria.
Perazella M, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clinical Nephrology 1998, 50: 194-6. PMID: 9776425.Peer-Reviewed Original ResearchConceptsRenal biopsy findingsRenal insufficiencyBiopsy findingsMild renal insufficiencyAcute renal failureIndinavir crystalsIndinavir therapyRenal failureAntiretroviral agentsUrinary obstructionAIDS patientsCellular castsPatientsPyuriaInsufficiencyRecent reportsSmall percentDiscontinuationNephropathyMedicationsSecond caseDiuresisNephrolithiasisIndinavirObstructionMidodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clinical Nephrology 1998, 50: 101-7. PMID: 9725781.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionMidodrine therapyHD sessionSafe therapyEnd-stage renal disease patientsStage renal disease patientsAlpha-1 adrenergic agonistMean ultrafiltration volumeSignificant causative roleRenal disease patientsTreatment-related factorsPatient-specific factorsMost therapeutic interventionsKt/VHypotensive symptomsBlood pressureHemodialysis patientsHD patientsDisease patientsSubjective improvementAdverse reactionsFrustrating complicationMean albuminSafe treatment